|By PR Newswire||
|March 3, 2014 06:00 AM EST||
LOS ANGELES, March 3, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 5:00 pm PT, at the Ritz-Carlton Hotel, Laguna Niguel, CA.
To access the live audio webcast of the ROTH presentation, please log on through a link located in the Investors section of ImmunoCellular's website at www.imuc.com, under the Events & Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.
For ImmunoCellular Therapeutics, Ltd.
SOURCE ImmunoCellular Therapeutics, Ltd.
Sep. 25, 2016 03:15 AM EDT Reads: 3,336
Sep. 25, 2016 03:00 AM EDT Reads: 1,424
Sep. 25, 2016 02:45 AM EDT Reads: 1,689
Sep. 25, 2016 02:45 AM EDT Reads: 853
Sep. 25, 2016 02:15 AM EDT Reads: 1,202
Sep. 25, 2016 12:45 AM EDT Reads: 1,927
Sep. 25, 2016 12:45 AM EDT Reads: 1,031
Sep. 25, 2016 12:30 AM EDT Reads: 1,587
Sep. 24, 2016 09:45 PM EDT Reads: 1,604
Sep. 24, 2016 09:00 PM EDT Reads: 1,427
Sep. 24, 2016 08:30 PM EDT Reads: 1,443
Sep. 24, 2016 08:00 PM EDT Reads: 1,652
Sep. 24, 2016 07:00 PM EDT Reads: 2,792
Sep. 24, 2016 06:45 PM EDT Reads: 1,485
If you’re responsible for an application that depends on the data or functionality of various IoT endpoints – either sensors or devices – your brand reputation depends on the security, reliability, and compliance of its many integrated parts. If your application fails to deliver the expected business results, your customers and partners won't care if that failure stems from the code you developed or from a component that you integrated. What can you do to ensure that the endpoints work as expect...
Sep. 24, 2016 04:30 PM EDT Reads: 1,512